Tags : mRNA

Pfizer and BioNTech Initiate P-II/III Global Study of its Lead

Shots: The companies commence global (Ex- China) P-II/III study to evaluate a modRNA candidate (BNT162b2, 30µg dose level in a 2 dose regimen) from their BNT162 mRNA-based vaccine program against SARS-CoV-2 The P-II/III study follows the US FDA’s guidance on clinical trial design, will evaluate up to 30,000 participants in a ratio (1:1)  aged 18 […]Read More

Pfizer with its Partner BioNTech Receives the US FDA’s Fast

Shots: The designation is based on preliminary data from P-I/II study assessing BNT162b1 including animal immunogenicity studies results that were released on Jul 01, 2020. Additionally, the early results of German trial evaluating BNT162b1 are expected in Jul 2020 The companies BNT162 mRNA-based vaccine program involves the evaluation of 4 investigational candidates developed to target […]Read More

Sanofi Expands its 2018 Collaboration with Translate Bio to Develop

Shots: Translate Bio to receive $425M up front consisting $300M in cash and $125M as equity investment at $25.59/ share representing a 50% premium to the 20-day moving average share price prior to signing. The company will receive ~$1.9B as milestones, including $450M milestones under the 2018 agreement and expects $360M in next few years […]Read More

Genmab and CureVac Collaborate to Develop mRNA-based Antibody Therapeutics

Shots: CureVac to receive $10M upfront, $22.2M equity investment, milestones and royalties on sales of the first product. The companies jointly develop the first program while Genmab to get an option to initiate an additional three programs during 5yrs. research term  CureVac will be responsible to develop first product up to IND, after that Genmab […]Read More